SCHEMBL5860797

SCHEMBL5860797

CN(C)CCn1cc2c(NC(=O)Cc3ccc(OCc4ccccc4)cc3)cccc2n1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 4/20 0.74
LTA4H P09960 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
ALOX5 P09917 2/20 0.44
LTB4R Q15722 1/20 0.43
LTB4R2 Q9NPC1 1/20 0.43
ADORA3 P0DMS8 2/20 0.43
ADORA1 P30542 2/20 0.43
CACNA1G O43497 2/20 0.42
CACNA1H O95180 2/20 0.42
CACNA1I Q9P0X4 2/20 0.42
EGFR P00533 2/20 0.42
ADORA2B P29275 2/20 0.42
ADORA2A P29274 1/20 0.42
S1PR1 P21453 1/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5862031 0.85 MCHR1 (1.00) MCHR1SMN1; SMN2EGFRALDH1A1
SCHEMBL5862827 0.84 MCHR1 (0.98) MCHR1SMN1; SMN2EGFRALDH1A1
SCHEMBL5862070 0.81 MCHR1 (0.74) MCHR1LTA4HSMN1; SMN2ALOX5ALDH1A1
SCHEMBL5862836 0.75 MCHR1 (0.82) MCHR1SMN1; SMN2ALDH1A1
SCHEMBL5862100 0.72 MCHR1 (0.77) MCHR1SMN1; SMN2EGFRALDH1A1
SCHEMBL5860794 0.71 MCHR1 (0.60) MCHR1LTA4HSMN1; SMN2ALDH1A1
SCHEMBL5862116 0.71 MCHR1 (0.60) MCHR1LTA4HSMN1; SMN2ALDH1A1
SCHEMBL6069412 0.70 MCHR1 (0.59) MCHR1LTA4HSMN1; SMN2ALDH1A1
SCHEMBL5862055 0.70 MCHR1 (0.74) MCHR1SMN1; SMN2
SCHEMBL5862074 0.69 MCHR1 (0.73) MCHR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7049307-B2 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2006-05-23 US claimed
US-20050187279-A1 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor ABBVIE INC. 2005-08-25 US claimed
US-20050137187-A1 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor ABBOTT LABORATORIES 2005-06-23 US claimed
US-7049307-B2 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor ABBOTT LABORATORIES (US) 2006-05-23 US disclosed
US-20050187279-A1 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor ABBVIE INC. 2005-08-25 US disclosed
US-20050137187-A1 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor ABBOTT LABORATORIES 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137187-A1 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor MCHR1, MCHR2, MC1R MCHR1 1/4885LTA4H 2805/4885SMN1; SMN2 770/4885
US-20050187279-A1 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor MCHR1, MCHR2, MC1R MCHR1 1/4885LTA4H 2805/4885SMN1; SMN2 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.